Bristol Myers Squibb Co. closed $10.05 below its 52-week high ($59.46), which the company reached on September 22nd.

CAMBRIDGE, Mass., September 25, 2024--2seventy bio, Inc. (Nasdaq: TSVT) today announced that the Company, in partnership with ...

Abecma, developed in partnership with Bristol-Myers Squibb, for treating patients with newly diagnosed multiple myeloma.

BMO Capital analyst Evan Seigerman maintained a Hold rating on Bristol-Myers Squibb (BMY – Research Report) today and set a price target ...

2seventy bio and Bristol Myers Squibb are pulling the plug on a late-stage study of ... suboptimal response to autologous stem cell transplant. The Cambridge, Mass., company said it expects the move ...

The hits just keep on coming for Bristol Myers Squibb staffers amid the company's cost-savings program.  | Bristol Myers ...

Besides stomach cancer, the FDA also raised a similar concern for PD-1 drugs in first-line esophageal squamous cell carcinoma ...

In a report released today, Carter Gould from Barclays maintained a Hold rating on Amgen (AMGN – Research Report), with a price target of ...

With an FDA action date of Sept. 26, Bristol Myers Squibb’s KarXT could soon be the first new type of schizophrenia drug in ...

Septerna, a clinical-stage biotechnology company pioneering a new era of GPCR-targeted drug discovery, today announced the appointments of multiple senior leaders to its drug development team, ...

As the FDA prepares to render a verdict on BMS’ closely watched schizophrenia drug, BioSpace takes a closer look at the ...

Bristol Myers Squibb has signed a lease for just under 50,000 square ... feet on George Road in a suburban office complex ...